Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (n

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needsLate-breaking data to be presented during the 2023 American Society of Clinical Oncology...

Related Keywords

United States ,Japan ,China ,American ,Davidp Carbone , ,Thoracic Oncology Center ,American Society Of Clinical Oncology ,Ohio State University Comprehensive Cancer Center ,Solove Research Institute ,Bristol Myers Squibb ,Company Opdivo ,European Union ,Drug Administration ,American Society Of Clinical Oncology Annual Meeting ,Clinical Oncology Annual ,Hazard Ratio ,Confidence Interval ,Clinical Oncology ,Annual Meeting ,James Cancer Hospital ,Solove Research ,Myers Squibb ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,